2 completed. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow margetuximab: new trials by email Literature Review of margetuximab trials Research Report on margetuximab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer margetuximab, Retifanlimab, Tebotelimab - Gastric Cancer, Gastroesophageal Junction Cancer | Phase 2 / Phase 3 | Completed | MacroGenics | 82 | 2019-09-30 | 2025-06-08 |
| Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer Margetuximab, Trastuzumab, Physician's choice of chemotherapy. - HER-2 Positive Breast Cancer, Metastatic Neoplasm | Phase 3 | Completed | MacroGenics | 624 | 2015-08-24 | 2025-03-17 |
Neoplasm Metastasis (1) · Stomach Neoplasms (1)
MacroGenics (2)
Germany (2) · Italy (2) · Poland (2) · South Korea (2) · United Kingdom (2) · United States (2) · Austria (1) · Belgium (1) · Canada (1) · China (1) · Czechia (1) · Denmark (1) · Finland (1) · France (1) · Israel (1)